SyntrFuge System for Facial Atrophy and Loss of Contour

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Newport Beach Site 1, Newport, CA
Facial Atrophy and Loss of Contour+1 More
SyntrFuge System - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether fat processed with the SyntrFuge system can be used for facial aesthetics and contouring. If successful, the fat will be injected into the treatment sites. The SyntrFuge System is used to treat facial atrophy and loss of contour. There is no placebo group in this trial. The SyntrFuge System has previously been approved by the FDA for a different condition.

Eligible Conditions

  • Facial Atrophy and Loss of Contour

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Facial Atrophy and Loss of Contour

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6 months

6 months
FaceQ Satisfaction surveys
Global Aesthetic Improvement Scale (GAIS)
Investigator's Satisfaction Scale

Trial Safety

Safety Progress

1 of 3

Other trials for Facial Atrophy and Loss of Contour

Trial Design

1 Treatment Group

SyntrFuge System
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: SyntrFuge System · No Placebo Group · N/A

SyntrFuge System
Device
Experimental Group · 1 Intervention: SyntrFuge System · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Newport Beach Site 1 · Newport, CA
Photo of california 1Photo of california 2Photo of california 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Facial Atrophy and Loss of Contour
0 CompletedClinical Trials

Who is running the clinical trial?

Syntr Health Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
236 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing and able to read and sign the informed consent and other study materials.
You have provided written informed consent prior to any study-related procedures.
You are ambulatory.
You are able to follow study instructions and complete study assessment tools including the subject diary.
You are a female of childbearing potential and you have a negative urine pregnancy test result
You agree to not undergo any other treatments or cosmetic procedures in the treatment area during the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.